











ASO VISUAL ABSTRACT


ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

Ekaterina Baron, MD¹ , Armando Sardi, MD, FACS¹ , Mary Caitlin King, BS¹ , Andrei Nikiforchin, MD¹ , Felipe Lopez-Ramirez, MD¹ , Carol Nieroda, MD¹ , Vadim Gushchin, MD, FACS¹ , and Panayotis Ledakis, MD² 

¹Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD; ²Department of Medical Oncology and Hematology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD

Colon-type systemic chemotherapy is associated with longer survival in patients with high-grade mucinous appendiceal cancer with unresectable peritoneal metastases who were

deemed surgical candidates but had a failed attempt of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (<https://doi.org/10.1245/s10434-022-11894-6>).



© Society of Surgical Oncology 2022

First Received: 11 May 2022
Accepted: 16 May 2022
Published Online: 22 June 2022

A. Sardi, MD, FACS
e-mail: asardi@mdmercy.com

DISCLOSURE The authors declare no conflicts of interest regarding the publication of this paper.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.